CCDC6 and cholangiocarcinoma: Other top recurrent fusions include EML4–ALK in lung adenocarcinoma (LUAD; 1.0%), CCDC6–RET in THCA (4.2%), and FGFR2–BICC1 in cholangiocarcinoma (CHOL; 5.6%).